Enno Spillner - Evotec AG Insider

EVOTF -- USA Stock  

USD 17.48  0.00  0.00%

CFO, Member of the Management Board
Mr. Enno Spillner was Chief Financial Officer and Member of the Management Board of Evotec AG since July 18, 2016. From April 2013 until June 2016 he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. He joined the 4SCs Management Board already in September 2005 as CFO. Before working for 4SC, Mr. Spillner was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, which he joined at the beginning of 1999. In this role he was, besides finance and controlling, responsible for managing investments in the equity portfolio and also held the position of interim Managing Director at two portfolio companies ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH. In September 2001, he also assumed the position as Management Partner of BioM VC Fund. He began his career at MediaPlus Spezialagentur fr Media GmbH, Munich. Since 2014 he has also been Member of the Supervisory Board and Chairman of the Audit Committee at Nanobiotix, Paris
Age: 46  CFO Since 2016      
49 40 5 60 81 0  http://www.evotec.com
Spillner earned his Dipl.Kaufmann degree at Universitaet Bamberg.

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Found 1 records

CFO Since

Eyal DeshehTeva Pharmaceutical Industries
2014

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance Indicators

Did you try this?

Run Companies Directory Now
   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Companies Directory

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and China Steel. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.